title: Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening.
abstract: BACKGROUND
  Our objective was to analyse the cost effectiveness of computed tomography (CT) screening for lung cancer in terms of the cost per long-term survivor, which has not been evaluated to date.
  
  
  METHODS
  Estimations were computed based on data from the Surveillance, Epidemiology, and End Results registries covering years 1999-2003. The design framework of our model allowed for the incorporation of multiple values taken from the epidemiological and clinical literature to be utilised for cost inputs, scope of patients screened, diagnostic staging, and survival percentages applied separately to two cohorts: age 40-79 and 60-79 years. This enabled the analysis of over 1400 scenarios, each containing a unique set of input values, for which the estimated cost per 5-year survivor (CP5YS) was compared between the symptom-detected and proactive screening approaches.
  
  
  RESULTS
  Estimated CP5YS were higher for the symptom-detected approach in all 729 scenarios analysed for the cohort ages 60-79 years, ranging from approximately $5800 to $116,700 increased cost per 5-year survivor (CP5YS). For the cohort ages 40-79 years, 75% of the 729 scenarios analysed showed increased CP5YS for the symptom-detected approach ranging from $5700 to $110,000 increased CP5YS. Total costs and total 5-year survivors were higher for the proactive screening method for all scenarios analysed across both cohorts with increases ranging from 50-256% and 98-309%, respectively.
  
  
  CONCLUSIONS
  The predicted increase in long-term survival with CT screening and the potential for better utilisation of health-care dollars in terms of CP5YS, particularly when screening patients over the age of 60 years, are critically important considerations in directing effective future lung cancer management strategy.
authors.affiliation: University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
authors.forename: A W
authors.initials: AW
authors.lastname: Castleberry
authors.forename: D
authors.initials: D
authors.lastname: Smith
authors.forename: C
authors.initials: C
authors.lastname: Anderson
authors.forename: A J
authors.initials: AJ
authors.lastname: Rotter
authors.forename: F W
authors.initials: FW
authors.lastname: Grannis
mesh_terms: D000328:Adult; D000368:Aged; D015982:Bias; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000191:economics / Q000401:mortality*; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D017741:Survivors; D014057:Tomography, X-Ray Computed
references.citation: MMWR Morb Mortal Wkly Rep. 2005 Jul 1;54(25):625-8
references.pmid: 15988406
references.citation: Int J Epidemiol. 1982 Sep;11(3):261-7
references.pmid: 7129740
references.citation: Cancer. 1999 Nov 1;86(9):1867-76
references.pmid: 10547562
references.citation: Health Serv Res. 1998 Apr;33(1):29-53
references.pmid: 9566176
references.citation: Health Care Financ Rev. 1997 Summer;18(4):51-76
references.pmid: 10175613
references.citation: J Clin Oncol. 2002 Feb 15;20(4):911-20
references.pmid: 11844811
references.citation: Chest. 1992 Apr;101(4):1013-8
references.pmid: 1313349
references.citation: J Natl Cancer Inst. 2000 Aug 16;92(16):1308-16
references.pmid: 10944552
references.citation: N Engl J Med. 2006 Oct 26;355(17):1763-71
references.pmid: 17065637
references.citation: Lung Cancer. 2003 Mar;39(3):327-30
references.pmid: 12609571
references.citation: J Natl Cancer Inst. 2006 Jun 7;98(11):724-5
references.pmid: 16757691
references.citation: Chest. 2002 May;121(5):1507-14
references.pmid: 12006436
references.citation: Chest. 2007 Jul;132(1):193-9
references.pmid: 17505036
references.citation: JAMA. 2003 Jan 15;289(3):313-22
references.pmid: 12525232
references.citation: J Clin Oncol. 2007 Jan 10;25(2):203-8
references.pmid: 17210941
references.citation: Cost Eff Resour Alloc. 2008 Feb 26;6:5
references.pmid: 18302756
references.citation: Ann Oncol. 1997 Oct;8(10):1031-9
references.pmid: 9402178
references.citation: Womens Health Issues. 1996 Sep-Oct;6(5):239-45
references.pmid: 8870502
references.citation: Chest. 2003 Aug;124(2):614-21
references.pmid: 12907551
references.citation: Eur J Cancer. 2001 Sep;37(14):1759-67
references.pmid: 11549429
references.citation: Chest. 2000 Jun;117(6):1568-71
references.pmid: 10858384
references.citation: Int J Cancer. 2008 Jun 1;122(11):2594-9
references.pmid: 18302157
references.citation: Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13
references.pmid: 11850344
references.citation: Cancer. 2003 Mar 1;97(5):1271-5
references.pmid: 12599235
references.citation: Can J Oncol. 1995 Dec;5(4):408-19
references.pmid: 8770457
references.citation: Drugs R D. 2003;4(4):243-8
references.pmid: 12848590
references.citation: Health Technol Assess. 2006 Jan;10(3):iii-iv, ix-x, 1-90
references.pmid: 16409881
references.citation: Cancer. 2001 Jul 1;92(1):153-9
references.pmid: 11443621
references.citation: Chest. 1997 Jun;111(6):1710-7
references.pmid: 9187198
references.citation: J Clin Oncol. 2004 Dec 15;22(24):4971-8
references.pmid: 15611512
references.citation: Chest. 2004 Apr;125(4):1413-23
references.pmid: 15078754
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Lancet. 1999 Jul 10;354(9173):99-105
references.pmid: 10408484
references.citation: Lung Cancer. 2001 Jun;32(3):227-36
references.pmid: 11390004
references.citation: Am J Surg Pathol. 2006 May;30(5):606-13
references.pmid: 16699315
references.citation: Med Care. 1995 Aug;33(8):828-41
references.pmid: 7637404
references.citation: JAMA. 2007 Mar 7;297(9):953-61
references.pmid: 17341709
references.citation: Lung Cancer. 2005 Apr;48(1):93-102
references.pmid: 15777975
references.citation: Oncologist. 2008 Jan;13(1):65-78
references.pmid: 18245013
references.citation: Ethn Dis. 2003 Fall;13(4):477-84
references.pmid: 14632267